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Kavita Kumar, MD; * and Victor Jimen& 
Nocardiosis occurs predominantly in immunocompro- 
mised patients. It has been extensively reported in solid- 
organ transplant recipients but rarely in bone marrow 
transplant recipients. In spite of better prognosis for trans- 
plant recipients owing to the newer immunosuppressive 
regimens, opportunistic infections, such as nocardiosis, 
lead to increased mortality unless diagnosed early and 
treated appropriately. Nocurdiu asteroides complex is 
the predominant pathogen in humans and includes three 
species: N; asteroides sensu stricto, A? farcinica, and h? 
nova. It is a soil-borne aerobic filamentous actinomycete 
that is usually introduced through the respiratory system. 
Sulfonamides are the traditional drug of choice and 
minocycline has been established as the second-line of 
treatment, but there have been only a few reports of treat- 
ment with doxycycline. Various regimens, including 
imipenem, amikacin, quinolones, and minocycline, have 
been reported with varying degrees of success. A com- 
bination of imipenem and amikacin has proved to be the 
most successful regimen to date, the downside being the 
renal adverse effects. This report presents a case of pul- 
monary nocardiosis after bone marrow transplantation 
successfully treated with doxycycline, and a review of 
the literature. 
CASE REPORT 
A 53-year-old man was admitted to hospital because of 
dyspnea, cough, and chest pain 6 months after an allo- 
geneic bone marrow transplant. He was on prednisone 
and cyclosporine for graft-versus-host-disease without any 
change in his immunosuppressive regimen in the 
previous 3 months, and prophylactic acyclovir, itracona- 
zole, and ciprofloxacin. The patient’s sister, the donor, 
was allergic to sulfonamides, so the patient was placed 
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on monthly pentamidine rather than trimethoprim- 
sulfamethoxazole. He developed dyspnea on exertion, 
dry cough, and right-sided pleuritic chest pain 3 weeks 
prior to admission with a 30 lb weight loss over 2 
months. He was afebrile with 99% oxygen saturation on 
room air and a normal lung examination. His white blood 
cell count (WBC) was 3 X 109/L, with 74% neutrophils; 
platelet count was 16 X lo’& and the lactate dehydro- 
genase (LDH) was 927 U/L. Chest roentgenogram showed 
a mass in the right upper lobe with a diameter of 3 cm, 
and computed tomography (CT) of the chest confirmed 
a thick-walled, irregular cavitating mass. The patient was 
initially treated with ciprofloxacin, clindamycin, and 
amphotericin B. He underwent a bronchoscopy, and Gram 
stain of the lavage fluid showed filamentous branching 
organisms. He was then started on amikacin (12 mg/k@d) 
and sulfadiazine (2 g/d) after a desensitization regimen, 
but he developed a skin rash after 2 days. He was then 
switched to azithromycin (500 mg/d) along with the 
amikacin. Repeat CT of the chest showed an increase in 
the size of the mass with new mass lesions. The patient 
subsequently underwent CT-guided aspiration biopsy of a 
mass lesion that grew N asteroides sensu stricto (sensitive 
to tetracycline, trimethoprim-sulfamethoxazole, imipenem, 
and ceftriaxone). Doxycycline was administered (100 mg 
twice a day), and the patient improved symptomatically, 
with resolution of lesions on CT of the chest. Amikacin 
was discontinued after 4 weeks. The patient is well 10 
months later on oral doxycycline with complete resolu- 
tion of the lesions shown on CT scan of the chest. 
DISCUSSION 
Sulfonamides have been the traditional drug of choice for 
nocardiosis, but there have been treatment failures, espe- 
cially in disseminated and central nervous system (CNS) 
disease. Doxycycline can be considered as an alternative 
treatment in these patients and in those allergic to sul- 
fonamides, as the present case. Doxycycline, like minocy- 
cline, is a lipophilic, longer acting semisynthetic 
tetracycline. It is absorbed almost completely in the prox- 
imal small bowel. It reaches a peak serum concentration 
of 5.0 to 5.4 kg/rnL 3 to 4 hours after a single oral dose 
of 200 mg and is maintained above a concentration of 
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Table 1. Characteristics of Patients with Nocardiosis Treated with Doxycycline 
Follow-up 
Case Gender 
Reference Age (vi 
Underlying 
Disease 
Presentation 
Diagnostic Procedure 
Nocardia 
Species Treatment* (mo) Surviving Months 
1’ 
23 
34 
45 
56 
67 
78 
8Q 
9 
M Liver cirrhosis, 
57 liver transplant 
M 
42 
Renal transplant 
M 
36 
F 
73 
78 
28 
M 
50 
M 
39 
M 
53 
AIDS 
Non-Hodgkin’s 
lymphoma 
Corticosteroids 
Systemic lupus Brain abscess 
etythematosus Open biopsy 
AIDS 
AIDS 
Bone marrow 
transplant 
Skin nodules, 
lung abscess 
Skin biopsy 
Lung abscess 
CT-guided biopsy 
transvalensis 
asteroides 
RUL pneumonia - 
US-guided biopsy 
Allergy to TMX 
Subcutaneous abscesses asteroides 
Culture of discharge 
Subcutaneous abscesses otitidis caviarum 
Culture of drainage 
asteroides 
Esophageal ulcer 
Endoscopic biopsy 
TMX prophylaxis 
Adrenal masses asteroides 
CT-guided adrenal biopsy 
Lung abscess asteroides 
CT-guided aspiration 
TMX (8), noncompliant, Yes 5 
relapsed 
PO DXY (1) 
IMP + PIP + CIP 
(25 d), failed 
TMX (8 d), failed 
Added PO DXY (4) 
CTZ + IV DXY (2 wk) 
PO DXY (4) 
TMX (7 d), pancytopenia 
CIP + PO DXY (9) 
MIN, vertigo 
OFL, minimal response 
Added PO DXY (3) 
TMX (4), failed, surgery 
TMX (3 wk), drug reaction 
AMK + CFT (2 wk) 
PO DXY (4 wk) 
PO DXY (unknown) 
IV DXY (2 wk), relapse 
TMX + IMP + AMK + CIP 
CIP + CLD (8 d), failed 
AMK (4 wk) + IV (4 wk) 
PO DXY (10) 
Yes 24 
Yes 4 
Yes 9 
Yes 3 
Yes 24 
Yes Unknown 
Yes 18 
Yes 10 
‘TMX = trimethoprim-sulfamethoxazole; DXY = doxycycline; IMP = imipanam; PIP = piparacillin; CIP = ciprcflcxacin; CTZ = ceftaidime; MIN = minocyclina; 
OFL = ofloxacin; AMK = amikacin; CFT = cefotatan; CLD = clindamycin. 
AIDS = acquired immunodeficiency syndrome; CT = computed tomography; RUL = right upper lobe; US = ultrasound; PO = per oral; IV = intravenous. 
1 pg/mL for 8 to 12 hours. Doxycycline has extensive tis- 
sue penetration because of its lipophilic properties and 
has a half-life of 18 to 22 hours, which allows therapeutic 
levels to be maintained with a single daily dose. It can 
be used in patients with renal failure, because it is 
excreted via the gastrointestinal tract as an inactive con- 
jugate and thus has relatively less impact on the intesti- 
nal microflora. Though minocycline is mainly excreted 
by the liver, it should be used cautiously in patients with 
renal failure, and in particular, the normal daily dose of 
100 mg twice a day should not be exceeded, because 
the protein catabolic effect of the drug is dose-depen- 
dent and can aggravate uremia. Minocycline has been 
associated with vertigo, which has seriously limited its 
use. Doxycycline is associated with minimal side effects, 
such as phototoxicity and decreased absorption with 
ingestion of antacids. It is associated with minimal drug 
interactions, unlike sulfonamides, which increase the risk 
of renal toxicity when used concomitantly with immuno- 
suppressives, like cyclosporine. In an in vitro study 
reported by Dewsnup and Wright,’ minocycline was the 
most active, with an MIC,, of 4 kg/mL against isolates of 
IV asteroides, whereas doxycycline inhibited 81% of the 
isolates at 2 kg/rnL and had an MIC,, of 8 pg/mL. 
On review of English language literature through a 
MEDLINE search 1966-1999, the authors found reports 
of eight patients with nocardiosis treated with various 
regimens, which included doxycycline, three with sub- 
cutaneous abscesses and six with deep organ involve- 
ment (Table 1). Of these eight patients, only two were 
treated with doxycycline alone and survived, one along 
with ciprofloxacin and survived, and four patients were 
treated with various regimens initially and doxycycline 
was added later because of poor response, relapse, or 
adverse effects, and all four patients survived. One patient 
(case 8) relapsed after 2 weeks on doxycycline with an 
initial response. The newer isolates were found to be 
resistant to doxycycline at an MIC above 128 p,g/mL and 
the patient was then treated with a combination of 
trimethoprim-sulfamethoxazole, imipenem, amikacin, and 
ciprofloxacin and survived.2-9 The duration of therapy 
ranged from 3 months to 10 months. The doses ranged 
from 100 mg per day to 200 mg per day. 
Clinical and bacteriologic cure is difficult in Nocar- 
dia infections owing to the tendency toward relapse and 
recurrence with these organisms. Optimal duration of 
treatment has not been defined, but clinical outcome has 
been shown to be related to the duration of therapy. No 
patient treated for 6 months or longer died as a result of 
nocardiosis. lo-l3 
The authors suggest that doxycycline can be used 
as an adjunct in patients allergic to sulfonamides, 
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patients with renal failure, and those with a high risk of 
renal toxicity (as in transplant recipients on immuno- 
suppressives). Nocurdia species are usually sensitive to 
tetracyclines in vitro, and sensitivities can be used as a 
guide for further management. At least 6 months of treat- 
ment after clinical resolution and continued for a longer 
period in immunocompromised patients or those with 
disseminated disease is recommended, with a prolonged 
follow-up. 
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